ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen & Co. 7th Annual Global Health Care Conference.CAMBRIDGE, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Cowen & Co. 7th Annual Global Health Care Conference will be webcast live. The presentation is scheduled to begin at 4:10 p.m. GMT (Greenwich Mean Time) See UTC. GMT - Universal Time 1 (11:10 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy ) on November 8, 2006, and will be given at The Landmark London Hotel in London, England. The presentation will provide an update on ImmunoGen. The webcast can be accessed through the "Investor Relations Investor relations The process by which the corporation communicates with its investors. " section of the ImmunoGen website, http://www.immunogen.com . Following the live webcast, a replay of the presentation will be available at the same location until November 15, 2006. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer . Five anticancer compounds are in clinical testing through ImmunoGen and the Company's Collaborators - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Amgen (formerly Abgenix), Biogen Idec, Biotest AG, Boehringer Ingelheim, Centocor, Genentech, Millennium Pharmaceuticals, Inc., and sanofi-aventis have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with sanofi-aventis. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion